{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:27:24Z","timestamp":1791502044580,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40264-021-01057-z","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T06:03:36Z","timestamp":1614924216000},"page":"645-660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Juan S.","family":"Lasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo A.","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"1057_CR1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nchembio.392","volume":"6","author":"H Fyrst","year":"2010","unstructured":"Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol. 2010;6:489\u201397.","journal-title":"Nat Chem Biol."},{"key":"1057_CR2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcb.20127","volume":"92","author":"T Sanchez","year":"2004","unstructured":"Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004;92:913\u201322.","journal-title":"J Cell Biochem."},{"key":"1057_CR3","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","volume":"55","author":"VA Blaho","year":"2014","unstructured":"Blaho VA, Hla T. Thematic review series: lysophospholipids and their receptors: an update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014;55:1596\u2013608.","journal-title":"J Lipid Res."},{"key":"1057_CR4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrd2356","volume":"8","author":"D Marsolais","year":"2009","unstructured":"Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov. 2009;8:297\u2013307.","journal-title":"Nat Rev Drug Discov."},{"key":"1057_CR5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI76369","volume":"125","author":"RL Proia","year":"2015","unstructured":"Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125:1379\u201387.","journal-title":"J Clin Invest."},{"key":"1057_CR6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2400","volume":"8","author":"J Rivera","year":"2008","unstructured":"Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8:753\u201363.","journal-title":"Nat Rev Immunol."},{"key":"1057_CR7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/ibd\/izy269","volume":"25","author":"T P\u00e9rez-Jeldres","year":"2019","unstructured":"P\u00e9rez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, et al. Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts. Inflamm Bowel Dis. 2019;25:270\u201382.","journal-title":"Inflamm Bowel Dis."},{"key":"1057_CR8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","volume":"16","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16:495\u2013503.","journal-title":"Autoimmun Rev."},{"key":"1057_CR9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","volume":"25","author":"S-J Park","year":"2017","unstructured":"Park S-J, Im D-S. Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol Ther (Seoul). 2017;25:80\u201390.","journal-title":"Biomol Ther (Seoul)."},{"key":"1057_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17425255.2016.1196188","volume":"12","author":"P Juif","year":"2016","unstructured":"Juif P, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opin Drug Metab Toxicol. 2016;12:879\u201395.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"1057_CR11","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","volume":"6","author":"M Salvadori","year":"2006","unstructured":"Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006;6:2912\u201321.","journal-title":"Am J Transplant."},{"key":"1057_CR12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545\u201356.","journal-title":"Lancet Neurol."},{"key":"1057_CR13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med."},{"key":"1057_CR14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med."},{"key":"1057_CR15","unstructured":"US Food and Drug Administration. Gilenya (fingolimod): highlights of prescribing information. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022527s018lbl.pdf. Accessed 1 May 2020."},{"key":"1057_CR16","unstructured":"European Medicines Agency. Gilenya (fingolimod): summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf. Accessed 1 May 2020."},{"key":"1057_CR17","unstructured":"US Food and Drug Administration. Mayzent (siponimod): highlights of prescribing information. 2019. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209884s000lbl.pdf. Accessed 10 July 2019."},{"key":"1057_CR18","unstructured":"European Medicines Agency. Mayzent (siponimod): summary of product characteritics. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mayzent-epar-product-information_en.pdf. Accessed 18 Jan 2020."},{"key":"1057_CR19","unstructured":"US Food and Drug Administration. Zeposia (ozanimod): highlights of prescribing Information. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209899s000lbl.pdf. Accessed 25 June 2020."},{"key":"1057_CR20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41575-020-0293-9","volume":"17","author":"L Pouillon","year":"2020","unstructured":"Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol. 2020;17:365\u201376.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1057_CR21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40264-015-0336-2","volume":"38","author":"A Capogrosso Sansone","year":"2015","unstructured":"Capogrosso Sansone A, Mantarro S, Tuccori M, Ruggiero E, Montagnani S, Convertino I, et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Saf. 2015;38:869\u201388.","journal-title":"Drug Saf."},{"issue":"1554\u201373","key":"1057_CR22","first-page":"e12","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(1554\u201373):e12.","journal-title":"Gastroenterology"},{"key":"1057_CR23","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","volume":"53","author":"A Souto","year":"2014","unstructured":"Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology. 2014;53:1872\u201385.","journal-title":"Rheumatology"},{"key":"1057_CR24","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. Accessed 21 Feb 2021."},{"key":"1057_CR25","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. JAMA. 2000;283:2008\u201312.","journal-title":"JAMA"},{"issue":"264\u20139","key":"1057_CR26","first-page":"W64","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(264\u20139):W64.","journal-title":"Ann Intern Med."},{"key":"1057_CR27","first-page":"1","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:1\u20139.","journal-title":"BMJ"},{"key":"1057_CR28","first-page":"4","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:4\u201310.","journal-title":"BMJ"},{"key":"1057_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.msard.2019.05.026","volume":"33","author":"E Curti","year":"2019","unstructured":"Curti E, Tsantes E, Baldi E, Caniatti LM, Ferraro D, Sola P, et al. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis: an Italian multicentre study. Mult Scler Relat Disord. 2019;33:146\u201352. https:\/\/doi.org\/10.1016\/j.msard.2019.05.026.","journal-title":"Mult Scler Relat Disord."},{"key":"1057_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.msard.2014.06.005","volume":"3","author":"E Fox","year":"2014","unstructured":"Fox E, Edwards K, Burch G, Wynn DR, Laganke C, Crayton H, et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014;3:607\u201319. https:\/\/doi.org\/10.1016\/j.msard.2014.06.005.","journal-title":"Mult Scler Relat Disord."},{"key":"1057_CR31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75:320\u20137.","journal-title":"JAMA Neurol."},{"key":"1057_CR32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos L, Antel J, Comi G, Montalban X, O\u2019Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124\u201340.","journal-title":"N Engl J Med."},{"key":"1057_CR33","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1474-4422(16)30192-2","volume":"15","author":"L Kappos","year":"2016","unstructured":"Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016;15:1148\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(16)30192-2.","journal-title":"Lancet Neurol."},{"key":"1057_CR34","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263\u201373.","journal-title":"Lancet"},{"key":"1057_CR35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075\u201384.","journal-title":"Lancet"},{"key":"1057_CR36","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","volume":"85","author":"T Olsson","year":"2014","unstructured":"Olsson T, Boster A, Fern\u00e1ndez \u00d3, Freedman MS, Pozzilli C, Bach D, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014;85:1198\u2013208.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"1057_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00415-018-9117-z","volume":"266","author":"S Pfeuffer","year":"2019","unstructured":"Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, et al. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol. 2019;266:165\u201373. https:\/\/doi.org\/10.1007\/s00415-018-9117-z.","journal-title":"J Neurol."},{"key":"1057_CR38","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1177\/1352458511435984","volume":"18","author":"T Saida","year":"2012","unstructured":"Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler J. 2012;18:1269\u201377.","journal-title":"Mult Scler J."},{"key":"1057_CR39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","volume":"12","author":"K Selmaj","year":"2013","unstructured":"Selmaj K, Li DKB, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12:756\u201367.","journal-title":"Lancet Neurol."},{"key":"1057_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-017-0913-3","volume":"17","author":"A Achiron","year":"2017","unstructured":"Achiron A, Aref H, Inshasi J, Harb M, Alroughani R, Bijarnia M, et al. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. BMC Neurol. 2017;17:1\u201313.","journal-title":"BMC Neurol."},{"key":"1057_CR41","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bj\u00f6rck A, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79:950\u20138.","journal-title":"Ann Neurol."},{"key":"1057_CR42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/1352458518789884","volume":"25","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, et al. Efficacy and safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study. Mult Scler J. 2019;25:1255\u201362.","journal-title":"Mult Scler J."},{"key":"1057_CR43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18:1021\u201333.","journal-title":"Lancet Neurol."},{"key":"1057_CR44","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18:1009\u201320.","journal-title":"Lancet Neurol."},{"key":"1057_CR45","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00415-017-8642-5","volume":"264","author":"G Comi","year":"2017","unstructured":"Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing\u2013remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol. 2017;264:2436\u201349.","journal-title":"J Neurol."},{"key":"1057_CR46","doi-asserted-by":"crossref","first-page":"175628641877433","DOI":"10.1177\/1756286418774338","volume":"11","author":"BAC Cree","year":"2018","unstructured":"Cree BAC, Arnold DL, Cascione M, Fox EJ, Williams IM, Meng X, et al. Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Ther Adv Neurol Disord. 2018;11:1756286418774338.","journal-title":"Ther Adv Neurol Disord."},{"key":"1057_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:550\u201361. https:\/\/doi.org\/10.1053\/j.gastro.2019.10.035.","journal-title":"Gastroenterology"},{"key":"1057_CR48","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Feagan BG, Wolf DC, D\u2019Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754\u201362.","journal-title":"N Engl J Med."},{"key":"1057_CR49","doi-asserted-by":"publisher","first-page":"S-217","DOI":"10.1016\/S0016-5085(19)37337-8","volume":"156","author":"GR D\u2019Haens","year":"2019","unstructured":"D\u2019Haens GR, Danese S, Hibi T, Watanabe M, Davies M. 1005: a controlled trial of amiselimod, a selective S1P receptor modulator in Crohn\u2019s disease. Gastroenterology. 2019;156:S-217. https:\/\/doi.org\/10.1016\/S0016-5085(19)37337-8.","journal-title":"Gastroenterology"},{"key":"1057_CR50","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","volume":"384","author":"A Vaclavkova","year":"2014","unstructured":"Vaclavkova A, Chimenti S, Arenberger P, Holl\u00f3 P, Sator PG, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384:2036\u201345.","journal-title":"Lancet"},{"key":"1057_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2019-000354","volume":"6","author":"V Hermann","year":"2019","unstructured":"Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019;6:1\u201310.","journal-title":"Lupus Sci Med."},{"key":"1057_CR52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","volume":"20","author":"M Argollo","year":"2020","unstructured":"Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther. 2020;20:413\u201320. https:\/\/doi.org\/10.1080\/14712598.2020.1732919.","journal-title":"Expert Opin Biol Ther."},{"key":"1057_CR53","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb announces positive topline results from pivotal phase 3 true north trial evaluating Zeposia (ozanimod) in patients with moderate to severe ulcerative colitis. 2020. Available from: https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-announces-positive-topline-results-pivota. Accessed 24 June 2020."},{"key":"1057_CR54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1096\/fj.05-3730fje","volume":"19","author":"W Wang","year":"2005","unstructured":"Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P 4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 2005;19:1731\u20133.","journal-title":"FASEB J."},{"key":"1057_CR55","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cvr\/cvp086","volume":"82","author":"CK Means","year":"2009","unstructured":"Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res. 2009;82:193\u2013200.","journal-title":"Cardiovasc Res."},{"key":"1057_CR56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fphar.2017.00556","volume":"8","author":"A Cannavo","year":"2017","unstructured":"Cannavo A, Liccardo D, Komici K, Corbi G, de Lucia C, Femminella GD, et al. Sphingosine kinases and sphingosine 1-phosphate receptors: signaling and actions in the cardiovascular system. Front Pharmacol. 2017;8:556.","journal-title":"Front Pharmacol."},{"key":"1057_CR57","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2125.2012.04400.x","volume":"75","author":"E Legangneux","year":"2013","unstructured":"Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013;75:831\u201341.","journal-title":"Br J Clin Pharmacol."},{"key":"1057_CR58","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","volume":"167","author":"P Gergely","year":"2012","unstructured":"Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167:1035\u201347.","journal-title":"Br J Pharmacol."},{"key":"1057_CR59","doi-asserted-by":"crossref","first-page":"27343","DOI":"10.1074\/jbc.M116.740084","volume":"291","author":"J Zhao","year":"2016","unstructured":"Zhao J, Liu J, Lee J-F, Zhang W, Kandouz M, VanHecke GC, et al. TGF-\u03b2\/SMAD3 pathway stimulates sphingosine-1 phosphate receptor 3 expression: implication of sphingosine-1 phosphate receptor 3 in lung adenocarcinoma progression. J Biol Chem. 2016;291:27343\u201353.","journal-title":"J Biol Chem."},{"key":"1057_CR60","first-page":"1619","volume":"40","author":"A Hsu","year":"2012","unstructured":"Hsu A, Zhang W, Lee J-F, An J, Ekambaram P, Liu J, et al. Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int J Oncol. 2012;40:1619\u201326.","journal-title":"Int J Oncol."},{"key":"1057_CR61","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1158\/0008-5472.CAN-09-2722","volume":"70","author":"W Du","year":"2010","unstructured":"Du W, Takuwa N, Yoshioka K, Okamoto Y, Gonda K, Sugihara K, et al. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res. 2010;70:772\u201381.","journal-title":"Cancer Res."},{"key":"1057_CR62","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/cam4.1609","volume":"7","author":"F-J Lei","year":"2018","unstructured":"Lei F-J, Cheng B-H, Liao P-Y, Wang H-C, Chang W-C, Lai H-C, et al. Survival benefit of sphingosin-1-phosphate and receptors expressions in breast cancer patients. Cancer Med. 2018;7:3743\u201354.","journal-title":"Cancer Med."},{"key":"1057_CR63","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s13760-017-0794-7","volume":"117","author":"YD Fragoso","year":"2017","unstructured":"Fragoso YD. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. Acta Neurol Belg. 2017;117:821\u20137.","journal-title":"Acta Neurol Belg."},{"key":"1057_CR64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","volume":"72","author":"AM Arvin","year":"2015","unstructured":"Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72:31\u20139.","journal-title":"JAMA Neurol."},{"key":"1057_CR65","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/jamaneurol.2014.3390","volume":"72","author":"KL Tyler","year":"2015","unstructured":"Tyler KL. Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug. JAMA Neurol. 2015;72:10\u20133.","journal-title":"JAMA Neurol."},{"key":"1057_CR66","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1212\/NXI.0000000000000209","volume":"3","author":"A Mathias","year":"2016","unstructured":"Mathias A, Perriard G, Canales M, Vuilleumier F, Perrotta G, Schluep M, et al. The VZV\/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients. Neurol Neuroimmunol Neuroinflamm. 2016;3:e209.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1057_CR67","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","volume":"78","author":"N Jain","year":"2012","unstructured":"Jain N, Bhatti MT. Fingolimod-associated macular edema: Incidence, detection, and management. Neurology. 2012;78:672\u201380.","journal-title":"Neurology."},{"key":"1057_CR68","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1172\/JCI12450","volume":"108","author":"JG Garcia","year":"2001","unstructured":"Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108:689\u2013701.","journal-title":"J Clin Invest."},{"key":"1057_CR69","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nchembio804","volume":"2","author":"MG Sanna","year":"2006","unstructured":"Sanna MG, Wang S-K, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006;2:434\u201341.","journal-title":"Nat Chem Biol."},{"key":"1057_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0176174","volume":"12","author":"G Izquierdo","year":"2017","unstructured":"Izquierdo G, Damas F, P\u00e1ramo MD, Ruiz-Pe\u00f1a JL, Navarro G. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study. PLoS ONE. 2017;12:1\u201312.","journal-title":"PLoS ONE"},{"key":"1057_CR71","doi-asserted-by":"crossref","first-page":"102411","DOI":"10.1016\/j.msard.2020.102411","volume":"45","author":"C Pelayo","year":"2020","unstructured":"Pelayo C, Ciampi E, Uribe-San-Mart\u00edn R, Soler B, Reyes A, Vergara E, et al. Multiple sclerosis and related disorders: short report peripheral vascular events in a real-world cohort of multiple sclerosis patients using fingolimod. Mult Scler Relat Disord. 2020;45:102411.","journal-title":"Mult Scler Relat Disord."},{"key":"1057_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000548","volume":"6","author":"T Ziemssen","year":"2019","unstructured":"Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, et al. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurol Neuroimmunol Neuroinflamm. 2019;6:1\u201310.","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01057-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T07:38:20Z","timestamp":1623051500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01057-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01057-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"15 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Juan S. Lasa receives consulting and lecture fees from Sanofi-Aventis and Abbvie. Pablo A. Olivera receives consulting fees from Abbvie, Takeda, and Janssen and lecture fees from Takeda and Janssen. Stefanos Bonovas has no conflicts of interest that are directly relevant to the content of this article. Silvio Danese receives speaking, consultancy, or advisory board member fees from Abbvie, Ferring, Hospira, Johnson and Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, and Boehringer-Ingelheim. Laurent Peyrin-Biroulet receives honoraria from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, and Amgen, grants from Abbvie, MSD, and Takeda, and stock options from CT-SCOUT.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JL: bibliographic search; inclusion and exclusion of studies for systematic review and meta-analysis; quality assessment of included studies; meta-analysis and statistical analysis; draft elaboration. PO: bibliographic search; inclusion and exclusion of studies for systematic review and meta-analysis; draft elaboration. SB: quality assessment of included studies; meta-analysis and statistical analysis; critical review of draft. SD: quality assessment of included studies; critical review of draft; LPB: study design and conception; draft elaboration and critical review of draft. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}